|
**Overview**: Allergy Screen Panel**Introduction**: The Allergy Screen Panel is a diagnostic tool designed for general allergy screening using serum samples. In India, allergic diseases affect a large population, with allergic rhinitis prevalent in 20-30 percent of adults and 22-23.5 percent of adolescents per ISAAC and NFHS data, asthma in approximately 37.5 million cases, and overall atopy high due to indoor allergens (dust mite, cockroach) and outdoor pollen/mold. Sensitization is widespread in urban polluted areas and rural regions with seasonal exposures, leading to symptoms like sneezing, wheezing, itching, and recurrent infections. High morbidity arises from underdiagnosis in low-SES and rural populations, limited access to allergy specialists, delayed treatment, and overlap with respiratory infections. Per immunology practices aligned with ICMR guidelines, the test employs immunoassay for broad screening (total IgE and Phadiatop inhalant mix) over 1-2 days with high sensitivity and specificity, serving as an initial tool to identify atopy in patients with persistent unexplained symptoms. This diagnostic falls under general allergy screening and targets individuals with suspected allergic conditions, addressing the challenge of early detection to guide further specific testing and management. With elevated morbidity due to underdiagnosis in diverse Indian settings, the test supports public health efforts by enabling precise identification of atopy, facilitating timely intervention, reducing chronic burden, and improving quality of life. Its serum-based approach ensures reliable performance in India's varied laboratory environments.**Other Names**: Allergy Scr Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Developed as a broad screening tool with Phadiatop mix; in India, widely adopted in respiratory and allergy clinics for initial atopy assessment.**Purpose**: The test screens for 2 parameters including total IgE and Phadiatop to guide general allergy assessment, detect atopy, and inform need for specific allergen testing.**Test Parameters**: 1. Total IgE, 2. Phadiatop.**Pretest Condition**: No fasting required; patients should report persistent sneezing, wheezing, itching, nasal congestion, or unexplained respiratory/skin symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptom duration, triggers (dust, pollen, pets), family atopy history, environmental exposures, or previous allergic episodes.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated allergic conditions including chronic rhinitis or asthma, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible atopy, necessitating further investigation like specialist consultation or specific allergen panels. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Allergists, pulmonologists, or general practitioners should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Specific IgE panels, spirometry, or skin prick tests for confirmation.**Test Limitations**: The test may produce false negatives in low exposure or false positives in asymptomatic sensitization, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: ICMR Allergy Guidelines 2023, Indian Journal of Allergy Asthma Immunology 2024, ISAAC India Studies 2023-2025. |
